AI-Powered Drug Discovery Acceleration
BenevolentAI (benevolent.com) scores 74 out of 100 on Brand Analyzer, placing it in the Brand-Ready tier among Healthcare brands, Technology brands, SaaS brands, in the 41st percentile of 6855 Healthcare brands.
BenevolentAI is a UK-based artificial intelligence company, founded in 2013 and headquartered in London, that applies advanced AI and machine learning to biopharma drug discovery. The company is listed on Euronext Amsterdam (BAI) and uses a proprietary knowledge graph and ontologies developed over a decade to support scientific and executive decision-making. Its stated mission is to accelerate drug discovery and improve patient outcomes for biopharma organizations, scientists, and life science consultancies. Joanna Shields serves as CEO.
| Brand Name | BenevolentAI |
|---|---|
| Domain | benevolent.com |
| Industry | Healthcare, Technology |
| Founded | 2013 |
| Headquarters | London |
| CEO | Joanna Shields |
| Main Competitors | Exscientia (80/100), Recursion Pharmaceuticals (85/100), Insilico Medicine (83/100), Atomwise (78/100), Insitro, Schrödinger (87/100), XtalPi |
Moz Domain Authority 50/100 vs category average 40 / leader 95 - a strong backlink profile, so AI systems frequently encounter mentions of the brand.
Ranked #550,049 on the Tranco list of most-visited sites - modest traffic makes the brand easy for AI models to overlook.
No Wikipedia presence was found - a major gap, since Wikipedia is among the most heavily weighted sources in AI training data.
The homepage meta description reads "BenevolentAI (Euronext Amsterdam: BAI), a leader in applying advanced AI to accelerate biopharma drug discovery." (Meta description: 15 words (ideal length). OG description present and descriptive) - this is the summary AI engines are most likely to quote.
Structured data on the homepage: og:title, og:description, og:image, og:type, canonical. Adding Organization and FAQ schema would further help AI crawlers parse the brand's identity.
AI-crawler access: robots.txt present, no AI bot restrictions - robots.txt controls whether engines like GPTBot and ClaudeBot can read the site at all.
Detected tech stack: Nginx.
Social footprint: verified profiles on X (Twitter), LinkedIn, Facebook, Instagram, YouTube, GitHub - consistent profiles reinforce the brand's identity across the web.
0 Reddit mentions - community discussion signals real-world reputation to AI models.
Live results from asking a general-purpose AI assistant about the brand, checked September 2026.
When asked "What is BenevolentAI?", Claude could identify the brand as of September 2026. BenevolentAI is a UK-based clinical-stage AI drug discovery company that uses machine learning and knowledge graphs to identify new drug targets and repurpose existing drugs. It gained significant attention when its AI platform helped identify baricitinib as a potential treatment Best known for Using AI to identify baricitinib as a COVID-19 treatment.
When asked "Best brands similar to BenevolentAI?", Claude would recommend BenevolentAI as of September 2026. It's one of the most well-known names in AI-driven drug discovery and a natural reference point alongside companies like Insitro or Recursion Pharmaceuticals.
Common questions people ask in Google, ChatGPT, Claude, Gemini, Perplexity, and other AI search engines.
BenevolentAI's main competitors in Healthcare: Exscientia (80/100), Recursion Pharmaceuticals (85/100), Insilico Medicine (83/100), Atomwise (78/100), Schrödinger (87/100).
Sources: Brand Analyzer scan
BenevolentAI is a UK-based artificial intelligence company, founded in 2013 and headquartered in London, that applies advanced AI to biopharma drug discovery. It is publicly listed on Euronext Amsterdam under the ticker BAI. The company is led by CEO Joanna Shields and positions itself as a leader in applying AI to accelerate drug discovery and improve patient outcomes.
Sources: BenevolentAI official site
BenevolentAI has limited AI-search visibility, scoring 34/100 on Brand Analyzer's AI visibility composite (visibility 26, trust 29, recommendation 53). This estimates how likely AI engines like ChatGPT, Claude, Gemini and Perplexity are to know, trust, and recommend the brand.
Sources: BenevolentAI official site
BenevolentAI was founded in 2013. BenevolentAI operates in the Healthcare category. It is analyzed by Brand Analyzer across seven brand dimensions and AI-search visibility.
Sources: Wikidata
BenevolentAI is headquartered in London. BenevolentAI operates in the Healthcare category.
Sources: Wikidata
BenevolentAI applies advanced AI and machine learning to biopharma drug discovery. It combines a proprietary knowledge graph and ontologies, built over more than a decade, with AI models to help scientists and executives make more precise and confident decisions in the drug discovery process, with the aim of accelerating development and improving patient outcomes.
Sources: BenevolentAI official site
BenevolentAI scores 53/100 on Brand Analyzer's AI recommendation signal, indicating it is reasonably likely to be surfaced when AI assistants like ChatGPT suggest Healthcare options. Recommendation depends on crawlability, structured data, and category authority.
Sources: BenevolentAI official site
BenevolentAI can improve AI discoverability by strengthening structured data (Organization and FAQ schema), maintaining an accurate Wikipedia/Wikidata entity, earning authoritative citations, and keeping content crawlable for AI bots. Brand Analyzer measures these as visibility, trust, and recommendation signals.
Sources: BenevolentAI official site
BenevolentAI offers AI-driven drug discovery capabilities built on a proprietary knowledge graph and ontologies. These tools are designed to support biopharma decision makers, scientists, and executives in identifying drug targets and making informed decisions throughout the drug discovery and development process.
Sources: BenevolentAI official site
BenevolentAI's platform and services are used by biopharma decision makers, scientists, executives, and life science consultancies seeking to apply AI to drug discovery and development processes.
Sources: BenevolentAI official site
BenevolentAI is known for combining a proprietary knowledge graph and ontologies with advanced AI to support biopharma drug discovery. It is recognized as a publicly traded AI company (Euronext Amsterdam: BAI) focused on bridging scientific and technological approaches to accelerate decision-making in drug development.
Sources: BenevolentAI official site
BenevolentAI scores 34/100 for AI visibility - how well ChatGPT, Claude, Perplexity and Google AI Overviews can discover, identify and cite the brand.
BenevolentAI has a weak AI-visibility profile at 34/100 - a proxy for how readily ChatGPT, Perplexity and Google's AI Overviews can recognise and cite it. Its strongest area is recommendation likelihood (53/100) and its weakest is visibility (26/100). It benefits from a Wikidata knowledge-graph entry, a global traffic rank of #550,049 (Tranco) and a Moz Domain Authority of 50/100. The main gaps holding it back: no clear Wikipedia entity to anchor it in LLM training data, thin schema.org structured data and no llms.txt to steer AI to its best pages. In a live check, Claude could already identify BenevolentAI from memory (September 2026) - a sign these signals are paying off.
The score combines seven dimensions - name quality, digital presence, visual identity, messaging clarity, trust foundation, AI discoverability, and brand authority - into a single objective benchmark.
Ranked closest to BenevolentAI: Beaconcure (74/100), Benefits by Design (BBD) (74/100), BeniPlus (74/100), Capsule Technologies (Philips Capsule) (74/100).
A step up - brands to learn from: Zurich Insurance Group (81/100), ZOLL Data Systems (81/100).
Category leader: Booksy (96/100).
Brand Analyzer is built by DataEase AI. Track your brand in ChatGPT, Gemini and Perplexity.